We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics.

Cookies config

  • Necessary

    The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.

    _GRECAPTCHAgoogle.comOwnprovide antispam protection with the reCaptcha service6 months
    cc_cookie_acceptfidmag.orgOwnUsada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)1 any
    WEB_SESSIONfidmag.orgOwnCookie técnica: cookie de sessió PHP. Guarda l'id de sessió d' acabar la sessió

  • Analisys

    Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.

    _gaGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics2 anys
    _gat_gtag_UA_141706552_1Google AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Tracking per part de google per google analytics1 minut
    _gidGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds24 hores

ConfigureReject allAccept
Thursday, 01/09/2022


Deep brain stimulation in treatment-resistant schizophrenia. A combined open/double-blind crossover trial examining nucleus accumbens and ventral tegmental targets.


Deep brain stimulation (DBS) in which high frequency electrical pulses are delivered to specific brain areas through implanted electrodes, has an established place in the treatment of certain neurological disorders. It has also demonstrated encouraging results in patients suffering with refractory forms of obsessive-compulsive disorder and major depression. Its use in patients with treatment-resistant schizophrenia is also under active consideration, but so far trials are few. The only completed formal clinical trial to date (N=7), carried out partly by members of the current research group, found preliminary evidence of effectiveness in 3 treatment resistant schizophrenic patients given DBS to the nucleus accumbens, a dopamine-rich site of the brain.
The present study aims to further examine the efficacy and safety of DBS in the nucleus accumbens (N=4 patients) and to explore its potential effectiveness in a new site, the ventral tegmental area (N=4), the brain area that gives rise to dopamine projections to the nucleus accumbens and other brain regions implicated in schizophrenia. The trial will follow the design of our earlier trial: after a 6 month (or longer if necessary) open treatment phase, patients who meet predetermined criteria for improvement will undergo a 12-week crossover phase where the stimulation will be switched off for half the time under double-blind conditions. Extended posttrial follow-up (12+ months) will also be undertaken to monitor for long term adverse psychiatric effects.

Financing entity

Instituto de Salud Carlos III y cofinanciado por la Unión Europea.


166.980 €


We are part of
HH Província España
Contact us

Avda. Jordà, 8, 08035 Barcelona
Contact phone: 935 480 105
Online contact 



Reconocimientos a la calidad y la excelencia
Última modificación: 29/02/2024